Novavax vaccine performs well—including against variants

The COVID-19 news world saw a return of Monday-morning vaccine results this week. Novavax, a small biotech company based in Maryland, announced that its vaccine demonstrated 90% overall efficacy and 100% protection against moderate and severe COVID-19 disease.

These results come from a trial conducted in the U.S. and Mexico between January and April this year, at a time when the Alpha (or B.1.1.7) variant was becoming dominant here. Among almost 30,000 trial participants, 77 cases were observed: 63 in the placebo group and 14 in the vaccine group, for an efficacy of 90.4%. All of the moderate and severe cases (ten moderate, four severe) were observed in the placebo group.

Novavax even sequenced samples from 54 out of the 77 cases. The majority of those sequenced cases were variants of concern or variants of interest; Novavax’s vaccine demonstrated 93.2% efficacy against variants of concern/interest and 100% efficacy against non-concerning variants. This finding aligns with other vaccine studies suggesting that the COVID-19 vaccines developed on older versions of the virus still work well against variants, especially at protecting against severe disease and death.

This new vaccine uses a coronavirus protein—a different method from both Moderna/Pfizer (mRNA vaccines) and AstraZeneca/Johnson & Johnson (adenovirus vaccines). It’s given in two doses, three weeks apart. It had far fewer side effects than other COVID-19 vaccines, with small numbers of participants reporting sore arms and fatigue.

The Novavax vaccine is also comparatively easier to transport and store than other viruses; it can be stored at refrigerated temperatures. While it’s unlikely to be used in the U.S., it could be critical for vaccine rollouts in other parts of the world.

More vaccine data

  • COVID source shout-out: Bloomberg’s vaccine tracker
    Last week, the team behind Bloomberg’s COVID-19 vaccine tracker announced that the dashboard will stop updating on October 5. Thank you to this team for your work tracking the vaccine rollout!
  • The U.S. needs to step up its booster shot campaign
    New, Omicron-specific booster shots are publicly available for all American adults who’ve been previously vaccinated. But awareness of the shots and uptake so far are both incredibly low.
  • National numbers, September 25
    Nationally, official COVID-19 case counts continue to decline: reported cases are down about 11% last week compared to the prior week, while new COVID-19 patients in hospitals are down 10%. But signals from wastewater and variants suggest a fall surge may be starting soon.
  • COVID-19 risk factors that should lead to Omicron booster priority
    Unlike previous vaccination campaigns, the new Omicron boosters are available to all adults across the country who have been previously inoculated. But all previously-vaccinated Americans are not facing similar levels of COVID-19 risk.
  • Data considerations for the new Omicron-specific booster shots
    This week, the FDA and CDC authorized new booster shots from both Pfizer and Moderna that are tweaked to specifically target Omicron BA.4 and BA.5. Here are some data considerations for the new boosters.

Leave a Reply